Logo del repository
  1. Home
 
Opzioni

Successful treatment of rare dermatologic diseases with oral cyclosporine

STINCO, Giuseppe
•
PATRONE, Pasquale
•
Lautieri S
altro
De Francesco V
2002
  • journal article

Periodico
INTERNATIONAL JOURNAL OF IMMUNOTHERAPY
Abstract
Cyclosporine A has been shown to be a very versatile drug able to act on different diseases of immune pathogenesis. We present four cases of different drug-resistant dermatoses that showed no response to any of the previous treatments and that, because of the seriousness and extent of their clinical pictures, prompted us to use cyclosporine A. The dermatoses were the following: ulcerative lichen ruber planus, necrobiosis lipoidica, pyoderma gangrenosum and persistent light reaction. In all of the four cases the average attack dose was 4.5 mg/kg/day, which was gradually reduced. The treatment was then protracted for several months. The result was reepithelization of the ulcers and maintenance of the result after treatment suspension in necrobiosis lipoidica and in pyoderma gangrenosum. In the patients with erosive lichen ruber planus and persistent light reaction, cyclosporine A therapy provided a dramatic, although only temporary, improvement of the lesions. In all four patients, cyclosporine A proved to be an efficacious and manageable drug.
WOS
WOS:000178626800004
Archivio
http://hdl.handle.net/11390/877171
info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-0036399207
Diritti
metadata only access
google-scholar
Get Involved!
  • Source Code
  • Documentation
  • Slack Channel
Make it your own

DSpace-CRIS can be extensively configured to meet your needs. Decide which information need to be collected and available with fine-grained security. Start updating the theme to match your nstitution's web identity.

Need professional help?

The original creators of DSpace-CRIS at 4Science can take your project to the next level, get in touch!

Realizzato con Software DSpace-CRIS - Estensione mantenuta e ottimizzata da 4Science

  • Impostazioni dei cookie
  • Informativa sulla privacy
  • Accordo con l'utente finale
  • Invia il tuo Feedback